GSK Reports Q3 2026 Growth Driven by Specialty Medicines and HIV Portfolio
GSK reported third-quarter sales of GBP 8.9 billion, representing a 5% increase at constant exchange rates. This growth was primarily fueled by the specialty medicines segment, which saw a 15% rise driven by strong performance in HIV treatments like Cabenuva and respiratory products such as Nucala. Despite these gains, core EPS grew only 1% due to higher interest costs following the Nuvalent acquisition and increased R&D spending. The company is aggressively investing in its oncology pipeline, with R&D investment up 22%. While Shingrix saw a slight decline due to destocking in China, other areas like the meningitis portfolio and Apretude showed robust growth. Looking ahead, GSK has upgraded its full-year royalty guidance but warned of foreign exchange headwinds that could reduce annual sales by 1% and operating profit by 3%.
Tickers: $GSK
Topics: Pharmaceuticals Product Launch R&D Investment Revenue Growth Specialty Medicine
Read the full article at Motley Fool
Part of the story Edward Jones Reports Strong Q3 2026 Growth Driven by Advisory Assets and New Digital Solutions (22 articles)